Biomedical industrial park: the main carrier of the cluster development of China's biomedical industry

[China Pharmaceutical network industry trends] with the development of the times, people pay more and more attention to health issues, and health industry is also concerned by many enterprises Among them, biomedical industry has become a new engine of global economic development It is understood that China's biopharmaceutical Industrial Park is accompanied by high-tech zones Since the development of 1990s, it has formed industrial clusters including the Yangtze River Delta, the Pearl River Delta, the Bohai Rim region and the northeast region In addition, Henan, Hubei in the central region, Sichuan and Chongqing in the western region also show a good industrial foundation In the past 10 years, the total output value of China's pharmaceutical industry has continued to grow at a high speed According to incomplete statistics, there are nearly 5000 pharmaceutical enterprises in China, more than 80% of which are located in the park, while there are more than 500 industrial parks, including, provincial and other industries dominated by biomedicine Biopharmaceutical Industrial Park has become the main carrier of the cluster development of Chinese biopharmaceutical industry Among them, Zhongguancun National Independent Innovation Demonstration Zone in Beijing, Zhangjiang pharmaceutical Valley in Shanghai, BioBAY in Suzhou, Guanggu biological city in Wuhan, International Biological Island in Guangzhou and Tianfu life science and Technology Park in Chengdu are typical representatives of domestic biomedical industrial parks Beijing Cangzhou Bohai New Area biomedical industrial park: opens a new space for development "Now, the park has 9 listed companies, 13 national high-tech enterprises, 32 provincial high-tech enterprises, and 7 national class 1.1 new drug products with the world's first drugs..." In the biomedical industrial park with tower cranes and roaring machines, Lu Shitong introduced us as he walked along, "in the future, it will highlight the development of APIs, pharmaceutical preparations, modern Chinese medicine, large health industry and pharmaceutical characteristic town, forming a five in one development pattern of the whole industrial chain." The annual output value of Changshu Suyu biomedical industrial park is expected to be 4 billion yuan The total number of projects settled in Changshu Suyu biomedical industrial park has reached 9, with a total investment of over 1.7 billion yuan and an annual output value of 4 billion yuan It is understood that at present, the average investment per mu of these nine settled projects has exceeded 5 million yuan, and the average profit and tax per mu is expected to exceed 1 million yuan after the project is completed In the future, Changshu Suyu biopharmaceutical Industrial Park will focus on the industrialization and R & D service projects with international advanced level in new drugs, biotechnology and related fields, and introduce the best of the best Shenzhen's biological industry develops rapidly with an average annual growth rate of 20% Shenzhen has increased policy support to promote the concentration of industrial factors The biological industry has developed rapidly with an average annual growth rate of 20% It has cultivated two major biopharmaceutical industry clusters, Pingshan national biological industry base and international biological valley It has outstanding advantages in gene detection, biological information, medical imaging and other fields, and has cultivated a number of Chinese biopharmaceutical leaders, such as BGI and Mindray medical With 319 innovation carriers established, the biomedical industry is becoming a new driving force for economic growth in Shenzhen After 10 years of development, the number of parks radiated by Wuhan Optical Valley Biological city has increased to 9 After ten years of development, the total revenue of Wuhan National biological industry base in 2017 exceeded 120 billion yuan, radiating and driving the strategic layout of "one base and multiple parks" in Yichang, Shiyan, Ezhou, Jingmen, Tianmen, Huangshi, Huanggang, Xiantao and Enshi Each park has distinctive development characteristics, complementary industrial functions and differentiated production layout, forming the "Hubei model" of vigorous development of biological industry Style Shanghai Zhangjiang pharmaceutical Valley has incubated more than 400 biomedical enterprises Shanghai Zhangjiang pharmaceutical Valley has gathered enterprises with strong momentum of new drug research and development in China It has incubated more than 400 biomedical enterprises and is a professional base of China's biomedical industry The clinical approval rate of drugs here is more than three times the global average From here, more than 100 projects of more than 80 enterprises have been launched all over the country; 20 drugs have moved from the domestic market to the international market and passed the approval of overseas listing; on average, every day, there will be an international academic exchange activity in the field of biomedicine Summary: since the 1990s, biomedical industrial park has developed vigorously in the global scope, and Asia's biomedical industry has started, gradually forming a world pattern of leading in the United States, second in Europe and third in Asia Nowadays, under the guidance of national top-level design strategy, the domestic biomedical industry is gradually showing a trend of agglomeration development.